以信为眼, 洞察财经世界 00 0 4-17 几度铃羽而归,新荷 花再闯港交所。 近年来，多次闯关A股未果后再闯港交所的公司愈发增加，四川新荷花中药饮片股份有限公司（下 称"新荷花"）便是其中之一。 成立于2001年的新荷花，是我国第一家中药饮片GMP（药品生产质量管理规范）工厂，主营产品包括 毒性饮片、普通饮片。公司业务遍布中国境内大部分省份，并在海外扩展到中医药需求强劲的地区，如 越南和马来西亚。 可作为中药饮片的头部企业，为何会多次闯关A股均未果？现如今又正式转战港股，又将迎来怎样的命 运？ 在资本市场的征途中，新荷花的A股上市之路可谓是充满了坎坷与挑战。这家在中药饮片领域有着深厚 积累的企业，多次冲击A股上市，却屡战屡败，引发了市场的广泛关注和深入探讨。 新荷花在2011年11月25日创业板发审委工作会议上通过审核，但2012年过会后不久，就遭到员工举报， 称其存在财务造假行为，包括隐瞒关联交易、虚增企业利润等严重内控治理问题。尽管时任保荐机构和 申报会计师进行了核查并发表明确意见，监管机构也未对新荷花进行处罚，但这些举报问题仍让市场对 其财务数据的真实性产生怀疑，最终新荷花于2012年8月底撤回申请 ...

新华财经北京5月30日电近期，四川新荷花中药饮片股份有限公司（以下简称："新荷花"）递表港交 所，保荐机构为广发证券（香港）、农银国际。 新荷花主营业务中药饮片的研发、生产和销售。此前，新荷花曾多次尝试A股上市，但均未成功。 根据招股书，新荷花毛利率近年来逐渐下滑，2024年业绩增收不增利。此次赴港上市，公司拟募集资金 用于扩大中药饮片产能、拓展海外市场等。 中药饮片龙头毛利率逐年下滑 受利润率较低的医疗贸易公司及药店销售占比增加影响，新荷花毛利率呈逐渐下滑态势。2022年至2024 年，公司总毛利率分别为21.1%、18.5%、17.1%。 其中，公司毒性饮片毛利率从2022年的29.7%下降至2024年的19.1%。普通饮片毛利率从2022年19.6%下 降至2024年16.7%。 | | | | 截至12月31日止年度 | | | | | --- | --- | --- | --- | --- | --- | --- | | | 2022年 | | 2023年 | | 2024年 | | | | 実利 | 毛利率 | 毛利 | 毛利率 | 毛利 | 毛利率 | | | 人民幣千元 | હ | 人民幣千元 ...

Core Viewpoint - Sichuan Xin He Hua Chinese Medicine Co., Ltd. is attempting to list on the Hong Kong Stock Exchange after multiple failed IPO attempts, highlighting significant underlying issues that need to be addressed [1][5]. Financial Performance - Xin He Hua's revenue for 2022, 2023, and 2024 is approximately 780 million, 1.146 billion, and 1.249 billion yuan respectively, with corresponding net profits of 77.4 million, 104 million, and 89.1 million yuan [3]. - The company is experiencing a decline in profit margins, with gross profit margin decreasing from 21.1% in 2022 to 17.1% in 2024, particularly in toxic medicinal slices, which fell from 29.7% to 19.1% [3]. - The operating cash flow for 2024 is reported at -46,700 yuan, with trade receivables amounting to 5.58 billion yuan, representing 44.7% of revenue, indicating cash flow pressure [5]. Company Background - Established in 2001 and headquartered in Chengdu, Xin He Hua is one of the largest suppliers of Chinese medicinal slices, ranking second in China by revenue in 2023 [3]. - The company has a diverse product range, including toxic and ordinary medicinal slices, with operations extending beyond China to countries like Vietnam and Malaysia [3]. IPO History - Xin He Hua's IPO journey has been tumultuous, with the first attempt in 2010 being halted due to allegations of financial fraud, which claimed that a significant portion of its revenue was derived from fictitious transactions [4]. - The company made another attempt in 2020 but withdrew its application due to concerns over its core product competitiveness and internal controls [4]. Industry Challenges - The Chinese medicinal slice industry faces challenges such as price volatility in raw materials, which directly impacts pricing and costs [6]. - Xin He Hua's reliance on a limited product range poses risks; any changes in market demand or supply chain disruptions could significantly affect its performance [6].